interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Bupivacaine; Meloxicam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Bupivacaine; Meloxicam, and who makes it?

Bupivacaine; Meloxicam appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Bupivacaine; Meloxicam1 dosage-form group in the Orange Book
0generic makers listed
  1. Bupivacaine; Meloxicam appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Extended Release, Periarticular

Brand listed, no generic listed as marketed

Brand listed as marketed: Zynrelef Kit. No generic is listed as marketed.

2020202520302035204001brand 2021data datePatent 9592227 listed to expire 13 March 2034Patent 9913909 listed to expire 13 March 2034Patent 11253504 listed to expire 13 March 2034Patent 10398686 listed to expire 13 March 2034Patent 9744163 listed to expire 13 March 2034Patent 11413350 listed to expire 20 April 2035Patent 9694079 listed to expire 20 April 2035Patent 9801945 listed to expire 20 April 2035Patent 10213510 listed to expire 20 April 2035Patent 10098957 listed to expire 20 April 2035Patent 10632199 listed to expire 20 April 2035Patent 10898575 listed to expire 20 April 2035Patent 11083797 listed to expire 20 April 2035Patent 11083730 listed to expire 20 April 2035Patent 10980886 listed to expire 20 April 2035Patent 11844837 listed to expire 21 April 2036Exclusivity I-933 to 23 January 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 January 2027Exclusivity I-933 Zynrelef Kit
  • 13 March 2034Patent 9592227 drug product
  • 13 March 2034Patent 9913909
  • 13 March 2034Patent 11253504
  • 13 March 2034Patent 10398686 drug product
  • 13 March 2034Patent 9744163 drug product
  • 20 April 2035Patent 11413350
  • 20 April 2035Patent 9694079 drug product
  • 20 April 2035Patent 9801945 drug product

8 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.